Severe Pain — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for severe pain. 262 active patents protecting 7 drugs from 7+ originators. First major cliff: 2032. Daily refresh.

7
Approved drugs
262
Active US patents
61/100
Avg vulnerability
$1.6B
Annual revenue covered

Originators in Severe Pain

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Indivior 96 patents Purdue Pharma Lp 79 patents Purdue Pharma 40 patents Trevena 15 patents Fresenius Kabi 14 patents Generic (originally Boots Group) 14 patents Lavipharm 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating severe pain. Each bar = one year. Y-axis scaled to peak year (119 patents).

7
26
35
27
5
28
16
29
27
30
18
31
119
32
7
34
7
35
20
36
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Subutex
Buprenorphine Hydrochloride
 Indivior 96 62 $800M 2027-07-23
Subutex
BUPRENORPHINE
 Purdue Pharma Lp 79 71 $800M 2026-07-31
OxyContin
oxycodone
 Purdue Pharma 40 51 — 2028-10-09
Olinvyk
OLICERIDINE
 Trevena 15 71 — 2032-03-23
Dilaudid-Hp
Hydromorphone Hydrochloride
 Fresenius Kabi 14 46 — 2032-04-23
Advil
ibuprofen
 Generic (originally Boots Group) 14 70 — 2029-09-30
Catapres-Tts-1
CLONIDINE
 Lavipharm 4 54 — 2027-04-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236292 Subutex method of use 88 2027-01-10
8236292 Subutex method of use 88 2027-01-10
8236292 Subutex method of use 88 2027-01-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9522188 Subutex formulation 42 2035-04-24
9522188 Subutex formulation 42 2035-04-24
9522188 Subutex formulation 42 2035-04-24
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9248229 Dilaudid-Hp formulation 42 2034-03-12
9259421 Subutex formulation 42 2032-09-18

Related